If folks want to understand more about what Keith Knutson was speaking about, this document should help; he's one of the authors. It's rather large and it includes lots of clinical data papers so give it a chance to open. Combining with a Checkpoint inhibitor (i.e., AZN's PD1)in the tumor burden setting will be effective in my opinion. In the residual cells or surveillance stage, combining with CI isn't as necessary because T-Reg cells (immune suppressive ones) tend to go hand-in-hand with tumor volume and metastatic state.
"Tumor escape and progression under immune pressure."
News 
Market Data 
Discover 
